眩晕3号方治疗阴虚阳亢型原发性高血压患者35例临床疗效

Clinical Effect of 35 Patients Using Xuanyunfang No. 3 in the Treatment of Primary Hypertension

目的：探讨眩晕3号方治疗原发性高血压的临床疗效。方法：选取本院2013年3月~2014年2月收治的70例原发性高血压患者,随机分为对照组和治疗组各35例。在内科常规治疗基础上,对照组给予口服奥美沙坦酯片,治疗组在此基础上加服眩晕3号方,两组疗程均为4周,观察并比较两组患者的临床疗效、血压疗效以及内皮素、降钙素相关基因肽。结果：治疗组的临床疗效和血压疗效均优于对照组（P〈0.01）;两组患者治疗前后的ET、CGRP比较,组内均有差异（P〈0.01,P〈0.01）,且治疗组均优于对照组（P〈0.01）。结论：眩晕3号方能对阴虚阳亢型高血压患者临床效果显著,可能与降低ET、升高CRGP相关,值得在临床推广。

Objective： To investigate the clinical efficacy of Xuanyunfang No. 3 in the treatment of primary hypertension.Methods： 70 cases with primary hypertension in our hospital from March 2013 to February 2014 were randomly divided into a control group and a treatment group with 35 cases in each group. Based on the conventional treatment in both groups,the control group was given oral Olmesartan Medoxomil tablets,and the treatment group on the basis of the therapy in the control group was given Xuanyunfang No. 3. Two groups were treated for 4 weeks. Clinical effects,blood pressure effects,ET,CGRP were observed and compared between two groups. Results： Clinical effects and blood pressure effects were better in the treatment group than those in the control group（ P〈0. 01）; compared patients in two groups before and after treatment according to ET and CGRP,it showed differences between two groups（ P〈0. 01,P〈0. 01）,and the treatment group was better than the control group（ P〈0. 01）. Conclusion： Xuanyunfang No. 3 for treating primary hypertension patients has a significantly clinical effect,and it may be related to the decrease of ET and the increase of CRGP,which is worth promotion in clinics.